Key highlights
- Median time to treatment failure exceeded 48 weeks for brepocitinib versus 12 weeks for placebo
- Statistically significant p-values of <0.0001 achieved across primary and all key secondary endpoints
- Steroid-free quiescence at Week 48 reached 62% in the treatment group compared to 20% for placebo
- Resolution of macular edema observed in 42% of treated eyes versus 4.8% in the control group
- Supplemental New Drug Application (sNDA) filing scheduled for the first half of calendar year 2027
Phase 3 CLARITY Trial Outcomes
Roivant Sciences and Priovant Therapeutics reported that the Phase 3 CLARITY program met all primary and secondary objectives in treating non-infectious uveitis (NIU). In two identical trials, CLARITY-1 and CLARITY-2, the 45 mg once-daily dose of brepocitinib demonstrated a median time to treatment failure of more than 48 weeks. This result significantly outperformed the placebo group's 12-week median duration. The program also achieved high rates of steroid-free quiescence and resolution of macular edema despite utilizing a more aggressive steroid taper than historical industry trials. Consequently, the company intends to submit a supplemental New Drug Application to the FDA in the first half of calendar year 2027.
Clinical Significance and Patient Impact
- Establishment of a new benchmark for steroid-sparing benefit in the treatment of chronic ocular inflammation
- Achievement of therapeutic benefit despite a faster reduction of oral prednisone than precedent NIU trials
- Significant resolution of macular edema, addressing one of the leading causes of permanent vision loss
- Validation of the dual TYK2/JAK1 inhibition mechanism in treating debilitating ocular etiologies
- Maintenance of a safety profile consistent with previous clinical evaluations of the brepocitinib molecule
Expert Perspective on Therapeutic Shift
“The phenomenal results from the Phase 3 CLARITY program suggest that brepocitinib could meaningfully change how we treat non-infectious uveitis across multiple etiologies.”
Business and Financial Profile
Roivant Sciences operates using a Vant model, where specialized subsidiaries like Priovant Therapeutics develop targeted therapies. The company maintains a robust liquidity position, reporting $3.9 billion in cash and equivalents as of June 30, 2026, which was further bolstered by a $2.25 billion patent settlement with Moderna in July 2026. This capital supports a diverse pipeline, including the recently FDA-approved LISRAYA for dermatomyositis. Roivant currently holds a market capitalization of $25.22 billion. The positive CLARITY data follows other recent milestones, including the announcement of Phase 3 studies for mosliciguat and ongoing developments in cutaneous lupus erythematosus.
Up 10.6% since our story on 21 Oct: $34.92 when we broke it → $38.61 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $34.70 |
|---|---|
| 20 Oct | $34.92 |
| 21 Oct | $36.80 |
| 22 Oct | $37.45 |
| 23 Oct | $36.49 |
| 26 Oct | $36.05 |
| 27 Oct | $36.54 |
| 28 Oct | $37.11 |
| 29 Oct | $37.52 |
| 30 Oct | $36.91 |
| 2 Nov | $35.89 |
| 3 Nov | $36.04 |
| 4 Nov | $38.23 |
| 5 Nov | $36.62 |
| 6 Nov | $38.88 |
| 9 Nov | $40.67 |
| 10 Nov | $41.19 |
| 11 Nov | $41.85 |
| 12 Nov | $39.99 |
| 13 Nov | $39.53 |
| 16 Nov | $38.61 |
| Date | Announcement | Amount |
|---|---|---|
| 23 Sep 2026 | Topline results from proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosusSource: investor.roivant.com | – |
| 08 Sep 2026 | Positive results from Phase 2 PHocus study of mosliciguat in PH-ILD and announcement of Phase 3 PHrontier studySource: investor.roivant.com | – |
| 27 Aug 2026 | FDA approval of LISRAYA (brepocitinib) 30 mg for the treatment of adults with dermatomyositisSource: investor.roivant.com | – |
| 06 Aug 2026 | Financial results for the first quarter ended June 30, 2026, and business updateSource: investor.roivant.com | – |
| 20 May 2026 | Financial results for the fourth quarter and fiscal year ended March 31, 2026Source: investor.roivant.com | – |
| 03 Mar 2026 | Genevant Sciences and Arbutus Biopharma global patent settlement with ModernaSource: investor.roivant.com | $2.25 Billion |
Management commentary
“The phenomenal results from the Phase 3 CLARITY program suggest that brepocitinib could meaningfully change how we treat non-infectious uveitis across multiple etiologies.”
| Share price | $34.92 |
|---|---|
| Market cap | $25.2B |
| Revenue (annual) | $8M |
| 1-month price change | -12.20% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Roivant Sciences Ltd. announcing positive Phase 3 results for brepocitinib in non-infectious uveitis.
Track Roivant Sciences Ltd. live
Get the next Roivant Sciences Ltd. SEC filing seconds after it lands.